Physician profile
Bryan Truong
NPI 1225559362
$6,088.43
in general payments reported to CMS, 2019-2025
24 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $699 · 2021: $411 · 2022: $960 · 2023: $928 · 2024: $1,072 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038 · Entertainment: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.01 |
| Entertainment | $129.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $908.90 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $827.74 | 2020-2025 | Cequa |
| Alcon Vision LLC | $823.85 | 2019-2025 | Total30, Precision7, Simbrinza |
| Tarsus Pharmaceuticals, INC. | $451.34 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $319.92 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $291.60 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $273.51 | 2022-2025 | Tyrvaya, Ryzumvi |
| Optos, INC. | $247.22 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $219.99 | 2019-2023 | |
| Coopervision INC. | $208.74 | 2022-2025 | Myday Contact Lens, Onefit Contact Lens, Clariti Contact Lens |
| Dompe US, INC. | $197.55 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $188.04 | 2023 | Tepezza |
| Abbvie INC. | $157.29 | 2022-2025 | |
| Amgen INC. | $156.21 | 2024-2025 | Tepezza |
| Glaukos Corporation | $145.66 | 2024 | Radius |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $127.16 | 2019 | |
| Aerie Pharmaceuticals, INC. | $111.35 | 2019 | |
| Biotissue Holdings INC. | $103.48 | 2021-2024 | |
| Harrow Eye, LLC | $91.85 | 2024-2025 | Vevye |
| Ivantis, INC | $88.23 | 2020 | |
| Kala Pharmaceuticals, INC. | $67.74 | 2021-2022 | |
| Visioneering Technologies, INC. | $39.00 | 2019-2022 | |
| Shire North American Group INC | $24.29 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $17.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.